Crispr Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Oppenheimer lowered their Q1 2020 earnings per share estimates for Crispr Therapeutics in a research report issued on Wednesday, February 12th. Oppenheimer analyst S. Tuerkcan now anticipates that the company will earn ($1.00) per share for the quarter, down from their previous forecast of ($0.89). Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($1.07) EPS, Q3 2020 earnings at ($1.16) EPS, Q4 2020 earnings at ($1.14) EPS, FY2020 earnings at ($4.38) EPS, FY2021 earnings at ($4.80) EPS, FY2022 earnings at ($5.90) EPS, FY2023 earnings at ($3.52) EPS and FY2024 earnings at $1.11 EPS.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of ($0.68) by $1.19. The business had revenue of $77.00 million for the quarter, compared to analysts’ expectations of $39.08 million. During the same period in the previous year, the company earned ($0.92) earnings per share. Crispr Therapeutics’s quarterly revenue was up 76900.0% on a year-over-year basis.
Several other equities research analysts also recently weighed in on CRSP. Piper Sandler reaffirmed a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a research note on Thursday. ValuEngine downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a research note on Monday, December 16th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Finally, BidaskClub downgraded shares of Crispr Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, February 11th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $78.29.
Shares of CRSP opened at $55.80 on Monday. Crispr Therapeutics has a fifty-two week low of $30.75 and a fifty-two week high of $74.00. The firm’s 50 day moving average price is $57.63 and its 200 day moving average price is $53.03.
Several large investors have recently made changes to their positions in the business. Captrust Financial Advisors lifted its stake in shares of Crispr Therapeutics by 1,373.9% in the 4th quarter. Captrust Financial Advisors now owns 14,739 shares of the company’s stock worth $874,000 after acquiring an additional 13,739 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of Crispr Therapeutics by 672.8% in the 4th quarter. Cubist Systematic Strategies LLC now owns 47,140 shares of the company’s stock worth $2,871,000 after acquiring an additional 41,040 shares during the period. First Republic Investment Management Inc. acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $294,000. Marshall Wace LLP acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $145,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Crispr Therapeutics by 17.1% in the 4th quarter. Bank of New York Mellon Corp now owns 46,167 shares of the company’s stock worth $2,812,000 after acquiring an additional 6,736 shares during the period. 50.01% of the stock is currently owned by institutional investors.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $465,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Corporate insiders own 21.40% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What is diluted earnings per share (Diluted EPS)?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.